Breast cancer patient-derived organoids for the investigation of patient-specific tumour evolution
Authors:
- Serena MazzucchelliSerena Mazzucchelli
- Lorena SignatiLorena Signati
- Letizia MessaLMLetizia Messa
- Alma FranceschiniAFAlma Franceschini
- Arianna BonizziABArianna Bonizzi
- Lorenzo CastagnoliLCLorenzo Castagnoli
- Patrizia GaspariniPatrizia Gasparini
- Clarissa ConsolandiCCClarissa Consolandi
- Eleonora ManganoEMEleonora Mangano
- Paride PelucchiPPParide Pelucchi
- Ingrid CifolaICIngrid Cifola
- Tania CamboniTCTania Camboni
Open Access
- 27 June 2024
- journal article
- research article
- Published by Springer Nature in Cancer Cell International
- Vol. 24 (1) , 1-18
Abstract
Background: A reliable preclinical model of patient-derived organoids (PDOs) was developed in a case study of a 69-year-old woman diagnosed with breast cancer (BC) to investigate the tumour evolution before and after neoadjuvant chemotherapy and surgery. The results were achieved due to the development of PDOs from tissues collected before (O-PRE) and after (O-POST) treatment. Methods: PDO cultures were characterized by histology, immunohistochemistry (IHC), transmission electron microscopy (TEM), scanning electron microscopy (SEM), confocal microscopy, flow cytometry, real-time PCR, bulk RNA-seq, single-cell RNA sequencing (scRNA-seq) and drug screening. Results: Both PDO cultures recapitulated the histological and molecular profiles of the original tissues, and they showed typical mammary gland organization, confirming their reliability as a personalized in vitro model. Compared with O-PRE, O-POST had a greater proliferation rate with a significant increase in the Ki67 proliferation index. Moreover O-POST exhibited a more stem-like and aggressive phenotype, with increases in the CD24low/CD44low and EPCAMlow/CD49fhigh cell populations characterized by increased tumour initiation potential and multipotency and metastatic potential in invasive lobular carcinoma. Analysis of ErbB receptor expression indicated a decrease in HER-2 expression coupled with an increase in EGFR expression in O-POST. In this context, deregulation of the PI3K/Akt signalling pathway was assessed by transcriptomic analysis, confirming the altered transcriptional profile. Finally, transcriptomic single-cell analysis identified 11 cell type clusters, highlighting the selection of the luminal component and the decrease in the number of Epithelial–mesenchymal transition cell types in O-POST. Conclusion: Neoadjuvant treatment contributed to the enrichment of cell populations with luminal phenotypes that were more resistant to chemotherapy in O-POST. PDOs represent an excellent 3D cell model for assessing disease evolution.Keywords
Funding Information
- Ministero dell’Istruzione, dell’Università e della Ricerca (PRIN 2017 ID2017EA2NR)
This publication has 49 references indexed in Scilit:
- Response-based molecular subtyping—emergence of the third generation of breast cancer subtypesCancer Cell, 2022
- Breast cancerThe Lancet, 2021
- A single-cell atlas of the healthy breast tissues reveals clinically relevant clusters of breast epithelial cellsCell Reports Medicine, 2021
- Stem cells in tissues, organoids, and cancersCellular and Molecular Life Sciences, 2019
- Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder CancerCell, 2018
- Personalized Cancer Medicine: An Organoid ApproachTrends in Biotechnology, 2018
- A Living Biobank of Breast Cancer Organoids Captures Disease HeterogeneityCell, 2018
- Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter DropletsCell, 2015
- 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trialThe Lancet, 2007
- Mechanism of Action of Anti-Her2 Monoclonal Antibodies: Scientific Update on Trastuzumab and 2c42003